The past 50 years of psychiatric practice have seen a burgeoning of new types and classes of psychotropic agents for major and minor psychiatric disorders (Olfson et al. 1999, 2002; West et al. 2003). Along with new pharmacological modalities, there is increased understanding to support and recommend that psychotherapy be provided along with pharmacological treatments for disorders including schizophrenia, bipolar disorder, and major depression (American Psychiatric Association 1994, 1997, 2000a). In addition, guidelines and position papers have been provided by the American Psychiatric Association to assist its members and mental health professionals in understanding the complexities of providing combined treatments in the form of both psychotherapy and pharmacotherapy (American Psychiatric Association 1980, 2002a).